Cytokinetics Inc (CYTK) - Total Liabilities
Based on the latest financial reports, Cytokinetics Inc (CYTK) has total liabilities worth $2.10 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CYTK net asset momentum to track the company's year-over-year net asset growth rate.
Cytokinetics Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Cytokinetics Inc's total liabilities have evolved over time, based on quarterly financial data. See Cytokinetics Inc (CYTK) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Cytokinetics Inc Competitors by Total Liabilities
The table below lists competitors of Cytokinetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ivanhoe Mines Ltd.
TO:IVN
|
Canada | CA$1.76 Billion |
|
Eastroc Beverage Group Co Ltd
SHG:605499
|
China | CN¥16.40 Billion |
|
Wynn Resorts Limited
NASDAQ:WYNN
|
USA | $14.53 Billion |
|
Nova Ltd
TA:NVMI
|
Israel | ILA1.04 Billion |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
India | Rs31.09 Billion |
|
TMX Group Limited
TO:X
|
Canada | CA$45.63 Billion |
|
Accor S. A.
PA:AC
|
France | €7.03 Billion |
|
Symrise AG
F:SY1
|
Germany | €4.16 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Cytokinetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cytokinetics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytokinetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytokinetics Inc (2000–2025)
The table below shows the annual total liabilities of Cytokinetics Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.08 Billion | +35.60% |
| 2024-12-31 | $1.54 Billion | +26.96% |
| 2023-12-31 | $1.21 Billion | +7.84% |
| 2022-12-31 | $1.12 Billion | +87.91% |
| 2021-12-31 | $597.46 Million | +42.11% |
| 2020-12-31 | $420.42 Million | +39.79% |
| 2019-12-31 | $300.75 Million | +62.35% |
| 2018-12-31 | $185.24 Million | +0.15% |
| 2017-12-31 | $184.97 Million | +144.08% |
| 2016-12-31 | $75.78 Million | +62.46% |
| 2015-12-31 | $46.65 Million | +14.04% |
| 2014-12-31 | $40.90 Million | +42.29% |
| 2013-12-31 | $28.75 Million | +370.40% |
| 2012-12-31 | $6.11 Million | +32.99% |
| 2011-12-31 | $4.59 Million | -38.54% |
| 2010-12-31 | $7.48 Million | -64.69% |
| 2009-12-31 | $21.17 Million | -43.83% |
| 2008-12-31 | $37.69 Million | -32.04% |
| 2007-12-31 | $55.45 Million | -12.26% |
| 2006-12-31 | $63.20 Million | +253.09% |
| 2005-12-31 | $17.90 Million | -12.87% |
| 2004-12-31 | $20.55 Million | -86.74% |
| 2003-12-31 | $154.90 Million | +32.67% |
| 2002-12-31 | $116.76 Million | +0.33% |
| 2001-12-31 | $116.37 Million | +40.45% |
| 2000-12-31 | $82.86 Million | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more